Biopsy or Liquid Biopsy – That is the (New) Question
All cancers begin with one cell that decides NOT to do what it is supposed to do. It divides and grows. Could you have a microscopic cancer growing in your body now? The really scary answer is yes. So, what if there was a “test”, a simple blood test, that could screen for the presence of microscopic cancer before symptoms or the size of a tumor makes itself known?
Most of us know that cancers are diagnosed via a biopsy – a sample of tissue taken from a suspicious area, such as a mole (melanoma) or lung nodule. Biopsies are typically done with needles, scrapes, or other surgical tools and then the tissue sample is examined microscopically.
The usual screening tests recommended by physicians routinely check for just 5 cancers:
- Colon (colonoscopy)
- Breast (Mammogram)
- Lung (Chest X-ray for those at risk)
- Uterus (Pap)
- Prostate (PSA)
Yet the reality is that about 70% of cancer deaths are caused by cancers that are not typically screened for!
Most cancers, except skin, are found when symptoms present themselves – coughing, pain, bleeding, or something else which is out of the ordinary. By the time symptoms appear, cancer has likely been growing for a while. This often means that the cancer has progressed to a later stage and may require more advanced treatment options and, possibly, a different prognosis.
What if there was another way to screen for cancers?
Liquid Biopsies & Multi-Cancer Early Detection Tests (MCED)
Multi-Cancer Early Detection Tests (MCED) – a type of liquid biopsy – are coming to the forefront of concierge medical practices and can detect cancer signals at very early stages, often before any symptoms appear.
Think about that for a moment. An otherwise perfectly healthy 52-year-old male completes a “liquid biopsy” screening test that was offered by his concierge doctor as part of an overall healthy visit checkup, that shows a signal that may indicate an early cancer. These tests are also sensitive enough to provide the organ system where the signal originated. For example, the Galleri test by GRAIL screens for more than 50 cancers with a single blood draw. See the full list of cancers Galleri screens for here.

Disclaimer: The Grail Galleri test and any of the early Multi-Cancer Early Detection tests (MCED) currently available do NOT diagnose cancers. They screen for many of the deadliest cancers before symptoms appear, and include cancers that currently do not have recommended screening tests. These flagged findings can and should be discussed with your healthcare provider to explore appropriate follow-up tests to confirm if cancer is present.
Our carrier partner, John Hancock, offers the Galleri blood screening test to eligible John Hancock Vitality Plus Members at no charge! Learn more about this cutting-edge test and the impact it had on the life of our advisor and friend, Kelley King, in the video linked here.
How the MCED Test Works

MCED is a simple blood test that examines and evaluates the Cancer Cell Components in your blood to determine the presence of any cancer cell markers. Our bodies make new cells every day and eliminate others. A lot of “debris” floats around in your bloodstream that includes trailing fragments of cell materials and “unusual” protein components. The new technologies can determine if this cell material came from a potential cancer cell.
MCED is considered innovative and continues to be improved upon and studied. As a result, it may not yet be readily available through your healthcare provider or reimbursable through your insurance coverage. Therefore, an MCED blood test should NOT be a replacement for standard cancer screening tests your healthcare provider recommends and health insurance covers.
MCED is a new technology in the testing phase, so false negatives and positives may occur. However, this technology is already showing incredible promise in finding cancers in people who show no signs or symptoms. Do YOU want to be tested?

MCED and UNDERWRITING: PERCEPTION OF RISK
Here at AgencyONE, we see many cancer survivor cases that present as underwriting challenges. The underwriters have “the numbers”, the actuarial statistics on percentages and probabilities of recurrence. Underwriters evaluate a multitude of risk factors when assessing risk and assigning a risk classification: Substandard…or not. So, what if we add a “no cancer detected” result to an underwriting file of a breast cancer, colon cancer, or even a lung cancer survivor? Would that, or COULD that…make for a better perception of risk for the underwriting team and Medical Director?
THAT is the question!
Case Study
Mrs. Smith is a 72-year-old female who was diagnosed with breast cancer and had a mastectomy along with radiation 6 years ago. As part of her recent comprehensive physical exam, her doctor offered her the option to take a screening MCED test. Since MCED is still considered “experimental,” it requires a doctor’s order for the lab and is currently an out-of-pocket expense for most. Given Ms. Smith’s cancer history, she opted to take the test, and the APS AgencyONE received to support Mrs. Smith’s underwriting assessment included the results of her blood test, which showed No Cancer Signal Detected. This finding gave the underwriter greater confidence to view the risk more favorably than they might have without the MCED test in her health records.
AgencyONE stays abreast of emerging medical technologies to ensure that our AgencyONE 100 advisors and their clients are matched with the right carrier delivering the most favorable underwriting outcomes and pricing available.
We encourage you to call the AgencyONE Underwriting Team at 301.803.7500 to discuss your specific Cancer case to see if we can help you secure the Life Insurance protection your clients need at the best possible price.


























